Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Inform Genomics, a privately held company that utilizes a proprietary technology platform to discover and develop genomic-based, precision medicine products, and Translational Drug Development LLC (TD2) based in Scottsdale, Arizona, have announced a strategic collaboration leveraging Inform Genomics' proprietary technology platform and analytic capabilities to biopharmaceutical companies through TD2's oncology drug development services.
Subscribe to our email newsletter
"We are very pleased to establish this strategic collaboration with TD2, as we see significant synergies between Inform Genomics’ proprietary technology and analytics along with TD2’s world-class oncology drug development service," said Ed Rubenstein, MD, President and CEO of Inform Genomics.
"Developing predictive genomic-based networks of side effects of early product candidates may help identify subpopulations at risk during later stages of clinical trials."
"TD2’s focus on precision oncology solutions, coupled with Inform Genomics ability to understand individual patient risk for side effects, can give a more complete vision of personalized medicine that has the opportunity to significantly improve patient care," said Stephen Gately, PhD, President and CEO of TD2.
"Having a technology to determine who will or will not develop specific types of toxicities with a particular therapy or a new agent presents a much needed new aspect of personalized medicine," said Daniel D. Von Hoff, MD, FACP, and Chief Development Officer of TD2.
Translational Drug Development (TD2) is an oncology development organization that provides innovative services for oncology-focused biopharmaceutical companies